Dapagliflozin – structure, synthesis, and new indications
Dapagliflozin is a sodium-glucose co-transporter-2 (SGLT2) inhibitors used in the treatment of patients with type 2 diabetes. An aryl glycoside with significant effect as glucose-lowering agents, Dapagliflozin also has indication for patients with Heart Failure and Chronic Kidney Disease. This revie...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Pensoft Publishers
2021-08-01
|
| Series: | Pharmacia |
| Online Access: | https://pharmacia.pensoft.net/article/70626/download/pdf/ |